Competing interests
neuropsychiatric disorders
CEREBRAL PALSY
A contract research organization (Worldwide Clinical Trials), paid by the sponsor, supervised the conduct of the trial under the direction of the sponsor. An independent contract research organization (Worldwide Clinical Trials) were responsible for conducting MADRS assessments with blinded remote raters. The analysis of the data was performed by the contract research organization (Worldwide Clinical Trials); and the interpretation of the data was performed by the sponsor. GMG has consulted for Beckley Psytech, Boehringer Ingelheim, Clerkenwell Health, EVApharm, H Lundbeck A/S, Janssen Global Services, Novartis, Ocean Neurosciences, P1vital, Sage Therapeutics, Servier, Takeda and WebMD. GMG, MC, LM, SM, HS, CS, SCS, JT, SW, and EM are current or past employees of COMPASS Pathfinder. GMG, MC, LM, SM, HS, CS, JT, SW, and EM own shares or options in COMPASS Pathfinder. DF has received grant funding from MindMed, Neurolief, Perception Neuroscience, and Relmada Therapeutics. DF holds a patent for psychedelic drug treatment of neuropsychiatric disorders and cerebral palsy. DF, JRK, VOK, and SK-P were site investigators or sub-investigators for COMPASS Pathfinder during the clinical trial and received funding to conduct the study, and SK-P is a consultant for COMPASS Pathfinder, providing therapist training and mentorship, and clinical development. JRK has consulted for Clerkenwell Health and has received grant funding from the Health Research Board (ILP-POR-2022-030).